GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Oncolytics Biotech Inc.
Oncolytics Biotech is a biotech company developing oncolytic viruses to fight cancer. Its stock price represents a venture bet on the success of its innovative platform. The chart reflects high volatility associated with news about clinical trials and partnerships.
Share prices of companies in the market segment - Oncology platforms
Oncolytics Biotech Inc. is developing reovirus-based oncolytic immunotherapy for the treatment of various types of cancer. We classify it as an "Oncology Platform" because it offers an innovative viral approach to fighting tumors. The chart below illustrates the dynamics of this cutting-edge, yet high-risk, sector.
Broad Market Index - GURU.Markets
Oncolytics Biotech is a Canadian biotech company developing oncolytic viral therapy based on reovirus for the treatment of cancer. Its shares are part of the GURU.Markets index. The chart below shows how its performance compares to the overall US market.
Change in the price of a company, segment, and market as a whole per day
ONCY - Daily change in the company's share price Oncolytics Biotech Inc.
Oncolytics Biotech Inc.'s daily price change is a measure of the high volatility inherent in the oncology biotech sector. This indicator reflects the company's sensitivity to clinical trial news and is an important component of more complex risk assessment formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Oncolytics Biotech Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. A comparison with ONCY's performance, with its oncolytic virus platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Oncolytics Biotech is developing an innovative approach to cancer treatment using oncolytic viruses. Like many biotechs, its stock price is driven by lab news rather than economic cycles. These unique movements contribute to the diverse and complex volatility of the overall market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Oncolytics Biotech Inc.
Oncolytics Biotech Inc.'s year-to-date performance is the story of its oncolytic virus, pelareorepa. Its 12-month market cap depends entirely on clinical trial data, where the virus is used in combination with other drugs to treat breast and pancreatic cancer. Success could open a new approach in immuno-oncology.
Annual dynamics of market capitalization of the market segment - Oncology platforms
Oncolytics Biotech Inc. is a biotech company developing oncolytic virotherapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results and partnerships. The chart reflects the high risks and potential for breakthroughs in this cutting-edge field of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Oncolytics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its oncolytic viral therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Oncolytics Biotech Inc.
Oncolytics Biotech is developing an oncolytic viral therapy. Its monthly price is a barometer of its clinical success. Fluctuations on the chart reflect the publication of trial data, partnership news, and progress in regulatory dialogue, which determine the future of its innovative platform.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
Oncolytics Biotech develops oncolytic viral therapy—an innovative approach that uses a virus to infect and destroy cancer cells. The chart below shows the overall dynamics in the oncology platform sector, reflecting investor interest in breakthrough, yet risky, cancer treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies developing new cancer treatment platforms can surge or fall on trial news. The chart below shows the general trends. Is Oncolytics Biotech moving at its own pace?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Oncolytics Biotech Inc.
Oncolytics Biotech's weekly performance reflects the potential of oncolytic viruses to fight cancer. This Canadian company's stock price is responding to clinical trial data showing how their viral drug can stimulate the immune system to attack tumors.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Oncolytics Biotech is developing a virus therapy for cancer treatment. It's an innovative but risky approach. The entire biotech sector is sensitive to scientific news. The chart below helps separate the company's success from industry noise: are the weekly fluctuations driven by Oncolytics' progress or by general sentiment in the oncology field?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Oncolytics Biotech is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Oncolytics is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
ONCY - Market capitalization of the company Oncolytics Biotech Inc.
Oncolytics Biotech's market capitalization tells the story of the development of an oncolytic viral therapy (pelavarepogen) for cancer treatment. Its volatile chart reflects the long journey of clinical trials. Its dynamics reflect the market's assessment of its drug's potential in combination with other therapies for combating difficult-to-treat tumors.
ONCY - Share of the company's market capitalization Oncolytics Biotech Inc. within the market segment - Oncology platforms
Oncolytics Biotech is a pioneer in the development of reovirus-based oncolytic immunotherapy. Its market capitalization reflects the potential of its flagship drug for treating various types of cancer. The chart below shows how the market values this innovative approach, which uses viruses to fight tumors.
Market capitalization of the market segment - Oncology platforms
Oncolytics Biotech is a company developing oncolytic viral therapy for cancer treatment. The chart below shows the overall market capitalization of the oncology sector. Its dynamics reflect the strong interest in immunotherapy, which includes Oncolytics' innovative approach, which uses viruses to stimulate tumor attack.
Market capitalization of all companies included in a broad market index - GURU.Markets
Oncolytics Biotech is developing oncolytic viral therapy. Its market cap is a bet that its virus will stimulate the immune system to attack cancer cells. Its performance on the overall chart is yet another story about how science is trying to harness nature to fight disease.
Book value capitalization of the company, segment and market as a whole
ONCY - Book value capitalization of the company Oncolytics Biotech Inc.
Oncolytics Biotech's foundation is its capital and patents for a unique oncolytic virus that can selectively destroy cancer cells. This is a tangible, scientific foundation for an innovative approach in immuno-oncology. How has this biotech asset changed during clinical trials? The chart below shows its dynamics.
ONCY - Share of the company's book capitalization Oncolytics Biotech Inc. within the market segment - Oncology platforms
Oncolytics Biotech is developing an oncolytic virus to combat cancer, which requires laboratory and manufacturing capabilities. The chart shows the share of these unique biotech assets, reflecting the physical foundation of its innovative therapeutic platform.
Market segment balance sheet capitalization - Oncology platforms
Oncolytics Biotech develops viruses to fight cancer. This innovative approach places its core value in the scientific platform. The book value chart shows how "light" the company's financial base is at the forefront of oncology.
Book value of all companies included in the broad market index - GURU.Markets
Oncolytics Biotech uses viruses to fight cancer. Its book value is derived from its production facilities for the oncolytic virus peliarepogen, its laboratories, and its R&D centers. The chart shows the material foundation on which this innovative immunotherapy platform is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Oncolytics Biotech Inc.
Oncolytics Biotech owns patents, not factories. Its market value reflects its belief in its oncolytic virus-based platform. The chart shows the "hope factor" investors are placing on its ability to create a new class of cancer drugs.
Market to book capitalization ratio in a market segment - Oncology platforms
Oncolytics Biotech is a pioneer in the development of oncolytic virotherapy. Its lead product is a virus that targets cancer cells. The chart reflects investor hopes that this innovative platform will lead to the development of a new class of anticancer drugs.
Market to book capitalization ratio for the market as a whole
Oncolytics Biotech is developing an oncolytic virus called pelareorep, which is designed to stimulate the immune system against cancer cells. The company's value lies in its unique viral platform. This chart shows the overall valuation, but how does the market value a biotech that uses viruses as a weapon for cancer immunotherapy?
Debts of the company, segment and market as a whole
ONCY - Company debts Oncolytics Biotech Inc.
Oncolytics Biotech is developing a platform based on oncolytic viruses. Its financial strategy involves conducting multiple clinical trials simultaneously. This chart shows how the company is using capital to test its drug in various cancer types, diversifying risk and increasing the chances of success.
Market segment debts - Oncology platforms
Oncolytics Biotech is a pioneer in the development of oncolytic viruses—viruses that can selectively destroy cancer cells. Developing this technology into an approved drug is a long road. This chart shows how the company funds its multi-year clinical research compared to other biotech innovators.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Oncolytics Biotech Inc.
Oncolytics Biotech is developing viral immunotherapy for cancer treatment. This chart shows how the company finances its cutting-edge research with debt. For investors, this allows them to assess the financial risk the company is taking in its quest to create a breakthrough drug that could change the paradigm of cancer treatment.
Market segment debt to market segment book capitalization - Oncology platforms
Oncolytics Biotech is developing an oncolytic viral therapy based on reovirus for the treatment of cancer. This chart reflects the collective debt burden in the capital-intensive biotech sector. It provides insight into how the industry as a whole finances its innovative platforms and how Oncolytics' capital raising strategy compares against this backdrop.
Debt to book value of all companies in the market
Oncolytics Biotech is developing oncolytic viral therapy. This is a cutting-edge field of biotechnology, financed through equity rather than debt. A chart of the economy's overall debt burden clearly demonstrates the difference between innovative companies burning through investors' cash to achieve breakthroughs and traditional businesses operating with leverage.
P/E of the company, segment and market as a whole
P/E - Oncolytics Biotech Inc.
For Oncolytics Biotech, which is developing oncolytic viral therapy, this chart illustrates investor expectations for its platform. The multiple is based on the belief in the potential of its virus to fight cancer, especially in combination with other drugs. This is an estimate of future clinical success, not current financial results.
P/E of the market segment - Oncology platforms
Oncolytic viruses, developed by Oncolytics Biotech, represent a new approach to cancer treatment. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Oncolytics is valued as a scientific platform, and the industry benchmark for profitable companies serves as a benchmark for its potential valuation if its therapy is successful.
P/E of the market as a whole
Oncolytics Biotech Inc. is a pioneer in the development of reovirus-based oncolytic virotherapy for cancer treatment. The company is evaluating its drug in combination with other treatments. This biotech sentiment chart helps understand how the market views the potential of this innovative platform and its numerous clinical programs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Oncolytics Biotech Inc.
Oncolytics Biotech is a biotech company developing reovirus-based oncolytic viral therapy for cancer treatment. This chart shows investor expectations based on clinical trial results. The dynamics reflect the market's confidence in the potential of its platform in combination with other therapies.
%20P%2FE%20Oncolytics%20Biotech%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Oncolytics-Biotech-Inc.&v=1772636370397 "Chart of the company's future (projected) P/E Oncolytics Biotech Inc.")
Future (projected) P/E of the market segment - Oncology platforms
Oncolytics Biotech is developing the oncolytic virus peliareporep, which is used in combination with other cancer treatments. This chart shows profitability expectations for the oncology sector. It helps understand how investors view the potential of this viral therapy to enhance the immune response against tumors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772636370427 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Oncolytics Biotech Inc. is developing a reovirus-based oncolytic immunotherapy for cancer treatment. This chart demonstrates investor appetite for innovation. For a biotech company with a unique viral platform, it reflects the market's willingness to invest in new approaches to cancer treatment that could complement existing methods.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636370473 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Oncolytics Biotech Inc.
Oncolytics Biotech Inc. is a pioneer in the development of reovirus-based oncolytic immunotherapy for cancer treatment. The financial results presented here represent investments in clinical programs to test the effectiveness of this platform. The chart shows the cost of advancing this innovative approach, which can activate the body's immune system to fight tumors.
Profit of companies in the market segment - Oncology platforms
Oncolytics Biotech is a biotech company developing the oncolytic virus peliareorep for the treatment of cancer. The drug stimulates the immune system to attack tumor cells. This graph highlights the potential of immuno-oncology, where innovative platforms like Oncolytics's could form the basis for combination therapies and significantly impact profitability.
Overall market profit
Oncolytics Biotech is developing oncolytic viral therapy—an innovative approach to cancer treatment. Like many biotech companies in the research stage, Oncolytics relies on external funding. A strong economy and growing corporate profits, as shown in this chart, create a stock market environment in which investors are more willing to fund breakthrough scientific ideas.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Oncolytics Biotech Inc.
Oncolytics Biotech is developing a reovirus-based oncolytic viral therapy to combat cancer. The earnings forecast presented here reflects analyst expectations based on clinical trial data and potential partnerships. This is a bet on the success of its unique immuno-oncology platform.
%20profit%20of%20the%20company%20Oncolytics%20Biotech%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Oncolytics-Biotech-Inc.&v=1772636370646 "Graph of future (projected) profit of the company Oncolytics Biotech Inc.")
Future (predicted) profit of companies in the market segment - Oncology platforms
Oncolytics Biotech is a pioneer in the development of reovirus-based oncolytic virotherapy for cancer treatment. Their drug, Pelareorep, is being studied in combination with other treatments. This chart shows the revenue forecast for oncology platforms, allowing one to assess the market's perception of the potential of this innovative approach to fighting cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772636370779 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Oncolytics Biotech is developing oncolytic viral therapy. Like other biotech companies, its prospects depend on scientific breakthroughs and funding. This graph, reflecting the overall risk appetite in the market, influences the influx of investment into innovative but risky medical fields, including Oncolytics.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636370898 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Oncolytics Biotech Inc.
Oncolytics Biotech is developing an oncolytic viral therapy based on the reovirus for the treatment of cancer. This chart shows how investors view the potential of its unique platform. The revenue estimate is a bet on its virus becoming an effective component of combination cancer therapy.
P/S market segment - Oncology platforms
Oncolytics Biotech is a pioneer in the development of oncolytic immunotherapy based on the reovirus, which can selectively destroy cancer cells. This chart shows the average market capitalization to revenue ratio for the biotech industry. It reflects how investors assess the potential of this innovative platform for treating various types of cancer.
P/S of the market as a whole
Oncolytics Biotech is developing oncolytic immunotherapy based on the reovirus (peliareorep) for the treatment of cancer. This innovative approach uses the virus to stimulate the immune system against tumors. This chart helps understand how the market values breakthrough, yet early-stage, technologies in the competitive field of oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Oncolytics Biotech Inc.
Oncolytics Biotech is developing an oncolytic viral therapy that can infect and destroy cancer cells. This chart shows the company's valuation relative to its projected future sales. It reflects investor expectations for the success of its clinical trials and the potential of its platform in combination with other treatments.
%20P%2FS%20Oncolytics%20Biotech%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Oncolytics-Biotech-Inc.&v=1772636371100 "The graph of the company's future (projected) P/S Oncolytics Biotech Inc.")
Future (projected) P/S of the market segment - Oncology platforms
Oncolytics Biotech is developing oncolytic immunotherapy based on the reovirus (peliareorep) for the treatment of various types of cancer. The company's platform is aimed at stimulating antitumor immunity. This chart shows how the market evaluates the potential of its unique viral platform compared to other oncology biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772636371122 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Oncolytics Biotech is developing oncolytic viral therapy for cancer treatment. The company's success depends on the results of clinical trials and partnerships. This graph of overall expectations for ONCY is merely a backdrop. The company's value is determined by investors' faith in its scientific platform, not by the overall economic situation. A scientific breakthrough will create its own trend.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636371138 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Oncolytics Biotech Inc.
This chart shows the financial model of a biotech company. For Oncolytics Biotech, it reflects revenue from partnerships with major pharmaceutical companies, which are jointly developing its oncolytic virus platform for the treatment of various types of cancer.
Sales of companies in the market segment - Oncology platforms
Oncolytics Biotech Inc. is developing an oncolytic viral therapy based on reovirus for the treatment of cancer. This platform can be used in combination with other drugs. This chart shows revenue for oncology platforms, and successful integration of Oncolytics' technology into standard treatments could significantly increase overall revenue for this segment.
Overall market sales
Oncolytics Biotech is a company developing oncolytic viral therapy. Its lead drug uses a virus to stimulate the immune system against cancer. The company's success depends on clinical trials and exemplifies an innovative approach in immuno-oncology, one of the fastest-growing and most promising segments in medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Oncolytics Biotech Inc.
Oncolytics Biotech is a pioneer in the development of oncolytic immunotherapy based on the reovirus, which selectively destroys cancer cells. Future sales projections depend on the success of clinical trials of this innovative platform. This chart shows the expected development of viral cancer therapy.
%20sales%20of%20the%20company%20Oncolytics%20Biotech%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Oncolytics-Biotech-Inc.&v=1772636371231 "Schedule of future (projected) sales of the company Oncolytics Biotech Inc.")
Future (projected) sales of companies in the market segment - Oncology platforms
Oncolytics Biotech Inc. is a pioneer in the development of oncolytic virotherapy. The forecast for the oncology platform sector demonstrates a general interest in innovative approaches. It helps us understand how the company's unique virus-based technology fits into the overall development of the oncology market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772636371238 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Oncolytics Biotech is developing oncolytic viral therapy for cancer treatment. Like other biotech companies, its prospects are tied to the success of clinical trials. This overall economic activity schedule doesn't impact its operations, but it may impact investor sentiment and the availability of funding needed to conduct expensive trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636371286 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Oncolytics Biotech Inc.
Oncolytics Biotech is the developer of the oncolytic viral therapy Pelareorep for cancer treatment. The company's financial picture is determined by the high costs of conducting numerous clinical trials. This chart does not represent current profits, but rather the cost of advancing an innovative oncology platform to potential commercialization.
Market segment marginality - Oncology platforms
Oncolytics Biotech develops oncolytic viral therapy for cancer treatment. Clinical-stage profitability is a long-term goal for the company, dependent on the success of clinical trials. This metric reflects its operational structure and the efficiency with which it deploys capital to advance its innovative platform compared to competitors.
Market marginality as a whole
Oncolytics Biotech Inc. is a biotech company developing oncolytic viral therapy for cancer treatment. This chart shows overall profitability. In this context, Oncolytics is another example of a company whose financial performance reflects research expenditures. Its story is not about current profitability, but about the potential of its scientific platform.
Employees in the company, segment and market as a whole
Number of employees in the company Oncolytics Biotech Inc.
Oncolytics Biotech is a pioneer in the field of immuno-oncolytic viral therapy. Its team of scientists and clinicians is working to advance its lead candidate, pelareorep. The staff increase, which can be seen in this chart, is directly related to the expansion of the clinical trial program in combination with other anticancer drugs.
Share of the company's employees Oncolytics Biotech Inc. within the market segment - Oncology platforms
Oncolytics Biotech is a pioneer in the development of reovirus-based oncolytic virotherapy for cancer treatment. This chart highlights its unique scientific niche. It reflects the share of leading virologists and immuno-oncologists working on this specific viral platform, attracting Oncolytics, which is at the forefront of cancer treatment innovation.
Number of employees in the market segment - Oncology platforms
Oncolytics Biotech is developing an oncolytic viral therapy based on reovirus for cancer treatment. This chart shows growth in the innovative oncology segment. The growth of the research team here signifies progress in clinical trials testing how the virus can stimulate the immune system to attack tumors.
Number of employees in the market as a whole
Oncolytics Biotech Inc. develops virological drugs to combat cancer. This is a cutting-edge field of science, and the company is in the research phase. Their staffing needs are determined not by the general labor market, as shown by this graph, but by progress in clinical trials. Success in the laboratory is the main driver for hiring new scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech is a pioneer in the development of reovirus-based oncolytic immunotherapy for cancer treatment. This chart demonstrates how the market values unique scientific platforms. The high market capitalization per employee suggests that investors see enormous value in the technology itself, which has potential for use in treating various tumor types.
%20of%20the%20company%20Oncolytics%20Biotech%20Inc.%20(ONCY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Oncolytics-Biotech-Inc.-ONCY&v=1772636371700 "Chart of market capitalization per employee (in thousands of dollars) of the company Oncolytics Biotech Inc. (ONCY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Oncolytics Biotech is developing virus therapy for cancer treatment. This is a cutting-edge scientific field, where the company's value is determined by its unique technological platform. This chart shows how the market values this platform's potential: the high cost per employee reflects investors' belief that a small team of scientists can revolutionize oncology.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772636371728 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Oncolytics Biotech is a pioneer in the development of oncolytic viral therapy. Its lead candidate, pelareorep, is being studied in various cancer types. This chart reflects the high valuation of the employee, as the company possesses an entire platform technology that can be applied to the treatment of a wide range of oncological diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636371753 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech is developing an oncolytic viral therapy (Pelareorep) that uses a virus to attack cancer cells and stimulate the immune system. It is an R&D company. This indicator is negative. It reflects how much the company invests in each employee (scientist, clinician) to prove the effectiveness of its viral platform in clinical trials.
%20Chart%20Oncolytics%20Biotech%20Inc.%20(ONCY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Oncolytics-Biotech-Inc.-ONCY&v=1772636371772 "Company Profit Per Employee (in thousands of dollars) Chart Oncolytics Biotech Inc. (ONCY)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Oncolytics Biotech (ONCY) is developing an oncolytic viral therapy (Pelareorep). This chart shows the average profitability level for the biotech sector. This level is not yet applicable to ONCY, which is in clinical development. Their goal is to prove that their platform can treat cancer. If successful, their intellectual property will allow them to generate profits far above average.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772636371789 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Oncolytics Biotech (ONCY) uses oncolytic viruses to fight cancer. It's another innovative biotech platform. At the clinical trial stage, this metric reflects not profit but investment in science. It shows the "cost" of maintaining an R&D team that advances this cutting-edge technology through the complex regulatory approval process.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636371847 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech is developing an oncolytic viral therapy. This chart shows that the company is in clinical trials, which is typical for biotech. It demonstrates the potential: if successful, its innovative platform could generate significant revenue, leading to explosive growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Oncolytics-Biotech-Inc.-ONCY&v=1772636371890 "Sales chart per company employee Oncolytics Biotech Inc. (ONCY)")
Sales per employee in the market segment - Oncology platforms
Oncolytics Biotech is developing an oncolytic virus-based platform (Pelareorep) to combat cancer. It is an R&D company. This metric reflects how effectively their research team generates revenue (through partnerships or grants) by advancing their viral platform through clinical trials, compared to other biotech companies.
Sales per employee for the market as a whole
Oncolytics Biotech is a biotech company developing an oncolytic virus (pelareorep) to stimulate the immune system against cancer. It's an R&D company. This chart shows revenue per employee. It's likely close to zero, reflecting revenue from partnerships rather than sales. It shows that the company's staff is focused on clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech is developing an oncolytic viral therapy (Pelareorep) that uses reovirus to fight cancer. This chart shows bearish bets. Bears doubt this platform will prove effective in key trials or that it will stand out among the many other immuno-oncology approaches in development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Oncolytics-Biotech-Inc.-ONCY&v=1772636372130 "Short Shares Chart for the Company Oncolytics Biotech Inc. (ONCY)")
Shares shorted by market segment - Oncology platforms
Oncolytics Biotech is developing an oncolytic viral therapy (Pelareorep) to combat cancer. This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies (e.g., the FDA) across the sector.
Shares shorted by the overall market
Oncolytics Biotech (ONCY) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, unprofitable biotechs like ONCY in order to move into safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech develops oncolytic viruses. The stock is highly speculative. This chart can surge above 70 on positive trial data or regulatory news, signaling euphoria. Oversold territory (<30) often reflects research setbacks, delays, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Oncolytics-Biotech-Inc.-ONCY&v=1772636372354 "RSI 14 indicator chart for the company's stock Oncolytics Biotech Inc. (ONCY)")
RSI 14 Market Segment - Oncology platforms
Oncolytics (ONCY) — "viruses against cancer." This biotech company "weapons" *reoviruses* (Pelareorep) to "explode" tumors from the inside. RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is ONCY's volatility due to its R&D or is the *entire* sector "overheated"?
RSI 14 for the overall market
Oncolytics Biotech (ONCY) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ONCY (Oncolytics Biotech Inc.)
Oncolytics Biotech is developing an oncolytic virotherapy (Pelareorep), a virus that infects and kills cancer cells. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of clinical trials for this innovative oncology platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ONCY-Oncolytics-Biotech-Inc.&v=1772636372570 "A chart showing analyst consensus forecasts for the expected stock price. ONCY (Oncolytics Biotech Inc.)")
The difference between the consensus estimate and the actual stock price ONCY (Oncolytics Biotech Inc.)
Oncolytics Biotech (ONCY) is a biotech company whose platform is based on an "oncolytic virus" (reovirus) that attacks cancer cells. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their viral immunotherapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ONCY-Oncolytics-Biotech-Inc.&v=1772636372598 "A chart showing the difference between the consensus forecast and the actual stock price. ONCY (Oncolytics Biotech Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Oncolytics Biotech is a pioneer in the field of "oncolytic viruses." The company uses a modified virus (Pelareorep) to "turn on" the patient's immune system to fight cancer. This chart shows general expectations for the onco-platform sector, reflecting whether experts believe in the commercial success of viral therapy.
Analysts' consensus forecast for the overall market share price
Oncolytics Biotech is a Canadian biotech company developing an "oncolytic" virus (Pelareorep) that infects and kills cancer cells and stimulates an immune response. This chart shows the overall risk appetite. For Oncolytics, which operates in a cutting-edge but high-risk field, overall market optimism is critical to funding long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Oncolytics Biotech Inc.
Oncolytics Biotech is a biotech company with a unique weapon: they use an oncolytic virus (Pelareorep)—a live virus that infects and kills cancer cells while simultaneously training the immune system to attack the tumor. This graph is a clear indicator of faith in their R&D platform. It reflects their progress in clinical trials (especially in breast cancer) and their partnerships.
AKIMA Market Segment Index - Oncology platforms
Oncolytics Biotech is a Canadian company developing an oncolytic viral therapy (Pelareorep). This is a virus that selectively infects and kills cancer cells. This chart shows the average index for the oncology sector. It allows investors to assess how Oncolytics' innovative platform compares to the average company based on aggregate metrics.
The AKIM Index for the overall market
Oncolytics Biotech is developing pelareorep, an immuno-oncolytic virus for the treatment of various types of cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this long-running scientific development in late-stage trials compares to overall economic trends.
